; The overall goal of the Functional Genomics/Genomic Sequencing Core (FGC) is to provide state-of-the-art instruments, and expert scientific and technical advice in cancer genomics to COHCCC investigators. The FGC is equipped with major genomics instrumentation such as Affymetrix GeneChip? Analysis System, Agilent scanner/microarray system, Roche NimbleGen MS200 microarray scanner/system, lllumina HiScanSQ, HiSeq2000, GA llx and Roche 454 FLX. The core also has a next-generation ABI Taqman Realtime PCR system ViiA 7 for microarray validation. FGC provides comprehensive genomic support including transcriptomic and mlRNA/smRNA profiling by,microarrays and RNA-Seq/smRNA-Seq, ChlP-Chip/ChlPSeq, DNA methylation, DNA-Seq including whole genome and target genome sequencing, microarray genome-wide and custom genotyping, SNP/CNV, aCGH, RNAi and qRT-PCR. The FGC has recently set up numerous new genomic technologies and assays including microarray-coupled genome-wide gene expression profiling using difficult clinical formalin-fixed paraffin-embedded (FFPE) RNA samples, smRNASeq and RNA-Seq using FFPE-derived samples, microfluidic chip- and microarray-coupled single-cell genome-wide gene expression profiling. In addition, the FGC has implemented NimbleGen array-based comprehensive high-throughput arrays for relative methylation (CHARM), Affymetrix DMET and genomewide human SNP 6.0 array genotyping, and lllumina Infinium HumanMethylation450 BeadChip that interrogates more than 450,000 methylation sites across the whole human genome at single-nucleotide resolution. The FGC has supported numerous NIH/NCI projects resulting in high impact publications. In summary, the advanced genomic tools in the FGC allow COHCCC investigators to: 1) identify cancer gene mutations at high-throughput rates;2) map cancer genomic, transcriptomic and epigenomic fingerprints to identify genomic biomarkers for cancer early detection and diagnosis;3) identify novel therapeutic targets against cancers;and 4) predict responses to therapy.

Public Health Relevance

The overall goal of the Functional Genomics Core facility is to provide state-of-the-art instruments, scientific and technical advice in cancer genomics. These allow us to potentially identify markers for cancer early detection and the novel targets for cancer therapy. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-31
Application #
8764848
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
31
Fiscal Year
2014
Total Cost
$229,842
Indirect Cost
$93,032
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076

Showing the most recent 10 out of 1277 publications